Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-2141
- Development stage
- Unknown
- Lead developer
- Addpharma
01
Overview
AD-2141 is an investigational drug developed by Addpharma, Inc. for the treatment of digestive system disorders, with a primary focus on gastroesophageal reflux disease (GERD). It has also been studied in the context of mouth and tooth diseases as well as otorhinolaryngologic diseases. The specific mechanism of action, molecular target, and modality for AD-2141 have not been publicly disclosed in available sources. A Phase 1 clinical trial compared the safety, pharmacokinetics, and pharmacodynamics of AD-214 to AD-2141 in healthy volunteers[2][3][9]. As of March 2025, its highest global R&D status is "Pending," with no regulatory approvals reported[2].
Beyond the preview
Go deeper on AD-2141.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-2141.